MITF



MITF (microphthalmia-associated transcription factor) is a protein that helps regulate the development, function, and survival of certain types of cells, particularly melanocytes. Melanocytes are specialized cells found in the skin and other tissues where they produce a pigment called melanin. This pigment gives color to the skin, hair, and eyes.

MITF plays a crucial role in cell function by controlling cell growth and pigment production genes. Changes in MITF function are associated with some types of cancer, particularly melanoma.

What types of cells and tissues normally express MITF?

MITF is typically found in cells that produce melanin, specifically melanocytes, which are found in the skin, eyes, and other pigmented tissues. It can also be present in some immune cells.

How do pathologists test for MITF?

Pathologists use immunohistochemistry (IHC) to detect MITF in tissue samples. In this test, antibodies bind specifically to the MITF protein if it is present in cells, resulting in a color change that can be observed under a microscope. This process allows pathologists to determine if MITF is present and assess the sample’s pattern and intensity of staining. The results are reported as either “positive” (MITF is present) or “negative” (MITF is absent), providing valuable information that can help identify specific types of cells or tumors, especially melanoma.

What types of benign (noncancerous) tumours express MITF?

Most benign (noncancerous) tumours that express MITF are found in the skin and are made up of melanocytes.

Examples include:

  • Nevi (moles) – Nevi are typically benign growths made up of melanocytes, so they often express MITF.
  • Pigmented spindle cell nevus – This benign lesion, found mainly on the skin, shows MITF expression and is considered a type of mole.
  • Lentigines are pigmented spots that often appear as flat, brown patches on the skin. They contain melanocytes and show MITF expression.

What types of malignant (cancerous) tumours express MITF?

MITF expression is seen in several malignant (cancerous) tumours, especially those derived from melanocytes.

Here are some cancers where MITF is commonly expressed:

  • Melanoma – MITF is frequently expressed in melanoma, where it plays a role in the tumour’s growth and survival.
  • Clear cell sarcoma – Also known as “melanoma of soft parts,” this rare cancer expresses MITF, linking it to melanocytic features.
  • PEComa (perivascular epithelioid cell tumour) – MITF can be found in some PEComas, rare tumours often involving the kidneys.
  • Renal cell carcinoma – Certain types of kidney cancer, particularly those with pigment-producing cells, may express MITF, although this is less common.

What genetic syndromes are associated with MITF?

Specific genetic changes in the MITF gene are associated with specific syndromes that affect pigmentation and sometimes increase cancer risk.

Syndromes associated with abnormal MITF include:

  • Waardenburg syndrome type 2 – This syndrome is characterized by pigmentary abnormalities of the skin, hair, and eyes, along with hearing loss. Changes in the MITF gene disrupt normal melanocyte function, leading to characteristic features such as patches of white hair, light blue eyes, or different-colored eyes.
  • Tietz syndrome – This rare syndrome is caused by a specific mutation in the MITF gene and leads to albinism-like features, such as pale skin and hair, and profound hearing loss from birth.
  • Familial melanoma syndrome – Some families have an inherited risk of melanoma due to specific MITF gene mutations. These changes can increase the likelihood of developing melanoma and sometimes other cancers, emphasizing the importance of regular screening for those with a family history of this condition.

These syndromes illustrate how changes in MITF function can impact pigmentation and may increase the risk for certain health conditions, particularly melanoma. Genetic testing and counseling are often recommended for individuals with these syndromes to guide monitoring and management.

How do pathologists test for genetic syndromes associated with MITF?

Pathologists and geneticists perform specialized genetic tests on DNA samples from blood or saliva to identify genetic syndromes linked to MITF. These tests analyze the MITF gene for specific mutations that can lead to health conditions like Waardenburg syndrome, Tietz syndrome, or familial melanoma syndrome. Key tests include:

  • DNA sequencing – This is the primary method used to examine the MITF gene. It reads the entire gene sequence, identifying any changes in the genetic code. DNA sequencing is highly accurate and can pinpoint mutations associated with MITF-related syndromes.
  • Targeted mutation analysis – For families with known MITF mutations, targeted analysis may be performed. This test focuses on specific areas of the MITF gene to detect known mutations quickly and is often used when a particular mutation has been previously identified in a family.
  • Multiplex ligation-dependent probe amplification (MLPA) – This test detects larger changes or deletions within the MITF gene that might not be identified by sequencing alone. MLPA helps detect structural alterations that may contribute to syndromic presentations.

Here is an example of a molecular pathology report for MITF:

Test: DNA sequencing of the MITF gene
Result: Heterozygous pathogenic variant detected in exon 8 of the MITF gene (c.952G>A; p.Gly318Arg)

Interpretation: A mutation was identified in the MITF gene associated with Waardenburg syndrome type 2. This variant, c.952G>A (p.Gly318Arg), is known to cause pigmentary abnormalities and hearing loss typical of the syndrome. This result confirms a diagnosis of Waardenburg syndrome type 2, and genetic counseling is recommended for the patient and family members.

In this example, a pathogenic variant in the MITF gene is reported. The result shows the specific mutation known to cause Waardenburg syndrome type 2, allowing for precise diagnosis and management planning.

A+ A A-

Did you find this article helpful?